Clear Street raised the firm’s price target on Protagonist Therapeutics (PTGX) to $91 from $74 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q3 report.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics Advances Pipeline Amid Financial Loss
- Promising Developments and Strategic Progress at Protagonist Therapeutics Drive Buy Rating
- Protagonist Therapeutics reports Q3 EPS (62c), consensus (64c)
- PTGX Earnings this Week: How Will it Perform?
- Protagonist Therapeutics price target raised to $88 from $76 at Truist